Bacteremia in Staphylococcus aureus pneumonia: Outcomes and epidemiology

Journal of Critical Care

Volumn 26, Issue 4, 2011, Pages 395-401

  Schreiber, Matthew P ^a   Chan, Chee M ^b   Shorr, Andrew F ^a  

^a WASHINGTON HOSPITAL CENTER   (United States)

^b GEORGETOWN UNIVERSITY   (United States)

Author keywords

Bacteremia; Epidemiology; Mortality; Outcomes; Pneumonia; Resistance

Indexed keywords

ANTIBIOTIC AGENT; HYPERTENSIVE FACTOR;

ADULT; ANTIBIOTIC THERAPY; ARTICLE; ARTIFICIAL VENTILATION; BLOOD CULTURE; CLINICAL FEATURE; COMORBIDITY; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG USE; FEMALE; HUMAN; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; OUTCOME ASSESSMENT; PREDICTIVE VALUE; RETROSPECTIVE STUDY; RISK ASSESSMENT; SCORING SYSTEM; SCREENING TEST; STAPHYLOCOCCAL BACTEREMIA; STAPHYLOCOCCAL PNEUMONIA;

ANTI-BACTERIAL AGENTS; APACHE; BACTEREMIA; COMORBIDITY; DRUG RESISTANCE, BACTERIAL; FEMALE; HOSPITAL MORTALITY; HUMANS; LENGTH OF STAY; LOGISTIC MODELS; MALE; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MIDDLE AGED; PNEUMONIA, BACTERIAL; PREVALENCE; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK FACTORS; SEVERITY OF ILLNESS INDEX; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS;

EID: 79960698586     PISSN: 08839441     EISSN: 15578615     Source Type: Journal    
DOI: 10.1016/j.jcrc.2010.09.002     Document Type: Article

References (19)

1. Liebowitz L.D. MRSA burden and interventions. Int J Antimicrob Agents 2009, 34:S11-S13.
2. Chastre J. Evolving problems with resistant pathogens. Clin Microbiol Infect 2008, 14:3-14.
3. Hidayat L.K., Hsu D.I., Quist R., et al. High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity. Arch Intern Med 2006, 166:2138-2144.
4. Cosgrove S.E., Sakoulas G., Perencevich E.N., et al. Comparison of mortality associated with methicillin-resistant and methicillin-susceptible Staphylococcus aureus bacteremia: a meta-analysis. Clin Infect Dis 2003, 36:53-59.
5. Kollef M.H., Shorr A.F., Tabak Y.P., et al. Epidemiology and outcomes of health-care-associated pneumonia: results from a large US database of culture-positive pneumonia. Chest 2005, 128:3854-3862.
6. Zilberberg M.D., Shorr A.F. Epidemiology of healthcare-associated pneumonia(HCAP). Semin Respir Crit Care Med 2009, 30:10-15.
7. Lynch J.P., Zhanel G.G. Streptococcus pneumoniae: epidemiology, risk factors, and strategies for prevention. Semin Respir Crit Care Med 2009, 30:189-209.
8. Rello J., Torres A., Ricart M., et al. Ventilator-associated pneumonia by Staphylococcus aureus. Comparison of methicillin-resistant and methicillin-sensitive episodes. Am J Respir Crit Care Med 1994, 150:1545-1549.
9. Rello J., Sole-Violan J., Sa-Borges M., et al. Pneumonia caused by oxacillin-resistant Staphylococcus aureus treated with glycopeptides. Crit Care Med 2005, 33:1983-1987.
10. Knaus W.A., Draper E.A., Wagner D.P., et al. APACHE II: a severity of disease classification system. Crit Care Med 1985, 13:818-829.
11. DeRyke C.A., Lodise T.P., Rybak M.J., et al. Epidemiology, treatment, and outcomes of nosocomial bacteremic Staphylococcus aureus pneumonia. Chest 2005, 128:1414-1422.
12. González C., Rubio M., Romero-Vivas J., et al. Bacteremic pneumonia due to Staphylococcus aureus: a comparison of disease caused by methicillin-resistant and methicillin-susceptible organisms. Clin Infect Dis 1999, 29:1171-1177.
13. Agbaht K., Diaz E., Muñoz E., et al. Bacteremia in patients with ventilator-associated pneumonia is associated with increased mortality: a study comparing bacteremic vs. nonbacteremic ventilator associated pneumonia. Crit Care Med 2007, 35:2064-2070.
14. Wunderink R.G., Rello J., Cammarata S.K., et al. Linezolid vs vancomycin: analysis of two double-blind studies of patients with methicillin-resistant Staphylococcus aureus nosocomial pneumonia. Chest 2003, 124:1789-1797.
15. Shorr A.F., Kunkel M.J., Kollef M. Linezolid versus vancomycin for Staphylococcus aureus bacteraemia: pooled analysis of randomized studies. J Antimicrob Chemother 2005, 56:923-929.
16. Rivera J., Vannakambadi G., Höök M., et al. Fibrinogen-binding proteins of gram-positive bacteria. Thromb Haemost 2007, 98:503-511.
17. Wilcox M.H., Tack K.J., Bouza E., et al. Complicated skin and skin-structure infections and catheter-related bloodstream infections: noninferiority of linezolid in a phase 3 study. Clin Infect Dis 2009, 48:203-212.
18. Vinh D.C., Rubinstein E. Linezolid: a review of safety and tolerability. J Infect 2009, 59:S59-S74.
19. Rybak M.J., Lomaestro B.M., Rotscahfer J.C., et al. Vancomycin therapeutic guidelines: a summary of consensus recommendations from the Infectious Diseases Society of America, the American Society of Health-System Pharmacists, and the Society of Infectious Diseases Pharmacists. Clin Infect Dis 2009, 49:325-327.